This article first appeared with Targeted Oncology™. An orphan drug designation (ODD) was granted by the FDA to elraglusib for the treatment of patients with soft tissue sarcoma (STS). 1 Currently, a ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results ...

Dedifferentiated liposarcoma is a fast-growing and more aggressive type of soft tissue sarcoma that originates as a well-differentiated sarcoma and has a typical diagnosis age of 40 to 60 years. DDLPS ...

— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with ...

Soft tissue sarcoma is a type of cancerous tumor that forms in the body’s soft tissues, such as muscle, fat, fibrous tissue, and blood vessels. If it occurs in the shoulder, it might feel like a ...

Sonnet BioTherapeutics Holdings, Inc. has announced an expansion of its Phase 1 SB101 clinical trial of SON-1010, a candidate immunotherapy, to evaluate its effectiveness in combination with the ...

Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the ...

Sarcoma is a type of cancer that originates in the bones or soft tissue. Soft tissue sarcoma (STS) most often begins in the arms and legs but can also occur in other body parts. Soft tissues include ...